WO2021195616A1 - Predicting wellness of a user with monitoring from portable monitoring devices - Google Patents
Predicting wellness of a user with monitoring from portable monitoring devices Download PDFInfo
- Publication number
- WO2021195616A1 WO2021195616A1 PCT/US2021/024617 US2021024617W WO2021195616A1 WO 2021195616 A1 WO2021195616 A1 WO 2021195616A1 US 2021024617 W US2021024617 W US 2021024617W WO 2021195616 A1 WO2021195616 A1 WO 2021195616A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- user
- value
- wellness
- assessment data
- predictive model
- Prior art date
Links
- 238000012544 monitoring process Methods 0.000 title claims abstract description 21
- 238000012806 monitoring device Methods 0.000 title description 16
- 238000000034 method Methods 0.000 claims abstract description 61
- 230000001149 cognitive effect Effects 0.000 claims abstract description 48
- 208000015181 infectious disease Diseases 0.000 claims description 52
- 208000035473 Communicable disease Diseases 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 15
- 238000013528 artificial neural network Methods 0.000 claims description 8
- 230000000306 recurrent effect Effects 0.000 claims description 7
- 230000002787 reinforcement Effects 0.000 claims description 6
- 238000000354 decomposition reaction Methods 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 238000002649 immunization Methods 0.000 claims description 3
- 210000001989 nasopharynx Anatomy 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000015654 memory Effects 0.000 description 20
- 230000006870 function Effects 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 238000012545 processing Methods 0.000 description 11
- 238000012549 training Methods 0.000 description 11
- 230000033764 rhythmic process Effects 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 9
- 206010016256 fatigue Diseases 0.000 description 9
- 208000025721 COVID-19 Diseases 0.000 description 8
- 238000004891 communication Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 230000003542 behavioural effect Effects 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 238000013459 approach Methods 0.000 description 6
- 208000026278 immune system disease Diseases 0.000 description 6
- 208000028454 lice infestation Diseases 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 208000002474 Tinea Diseases 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 238000003066 decision tree Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000036651 mood Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000007958 sleep Effects 0.000 description 5
- 230000003936 working memory Effects 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 238000013527 convolutional neural network Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010007134 Candida infections Diseases 0.000 description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
- 208000004204 Larva Migrans Diseases 0.000 description 3
- 206010035148 Plague Diseases 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 108091000054 Prion Proteins 0.000 description 3
- 206010044269 Toxocariasis Diseases 0.000 description 3
- 241000893966 Trichophyton verrucosum Species 0.000 description 3
- 206010054000 Type II hypersensitivity Diseases 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 208000006730 anaplasmosis Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000003984 candidiasis Diseases 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000010801 machine learning Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000008026 type II hypersensitivity Effects 0.000 description 3
- 208000026872 Addison Disease Diseases 0.000 description 2
- 208000000230 African Trypanosomiasis Diseases 0.000 description 2
- 206010001935 American trypanosomiasis Diseases 0.000 description 2
- 206010003267 Arthritis reactive Diseases 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- 206010044583 Bartonella Infections Diseases 0.000 description 2
- 206010005098 Blastomycosis Diseases 0.000 description 2
- 208000003508 Botulism Diseases 0.000 description 2
- 208000009802 Colorado tick fever Diseases 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 208000000307 Crimean Hemorrhagic Fever Diseases 0.000 description 2
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 2
- 206010059547 Cutaneous larva migrans Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 2
- 208000031912 Endemic Flea-Borne Typhus Diseases 0.000 description 2
- 201000005866 Exanthema Subitum Diseases 0.000 description 2
- 201000006353 Filariasis Diseases 0.000 description 2
- 201000000628 Gas Gangrene Diseases 0.000 description 2
- 206010018693 Granuloma inguinale Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 206010019143 Hantavirus pulmonary infection Diseases 0.000 description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
- 208000032982 Hemorrhagic Fever with Renal Syndrome Diseases 0.000 description 2
- 208000000464 Henipavirus Infections Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 208000000932 Marburg Virus Disease Diseases 0.000 description 2
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 206010028282 Murine typhus Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001263478 Norovirus Species 0.000 description 2
- 241000243985 Onchocerca volvulus Species 0.000 description 2
- 208000010195 Onychomycosis Diseases 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 2
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 2
- 208000000705 Rift Valley Fever Diseases 0.000 description 2
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 2
- 206010054979 Secondary immunodeficiency Diseases 0.000 description 2
- 206010061372 Streptococcal infection Diseases 0.000 description 2
- 208000007712 Tinea Versicolor Diseases 0.000 description 2
- 201000010618 Tinea cruris Diseases 0.000 description 2
- 206010056131 Tinea versicolour Diseases 0.000 description 2
- 208000004938 Trematode Infections Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 201000003486 coccidioidomycosis Diseases 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000000292 ehrlichiosis Diseases 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 206010014881 enterobiasis Diseases 0.000 description 2
- 230000008921 facial expression Effects 0.000 description 2
- 201000006061 fatal familial insomnia Diseases 0.000 description 2
- 201000005648 hantavirus pulmonary syndrome Diseases 0.000 description 2
- 208000029080 human African trypanosomiasis Diseases 0.000 description 2
- 201000009163 human granulocytic anaplasmosis Diseases 0.000 description 2
- 208000022340 human granulocytic ehrlichiosis Diseases 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000004015 melioidosis Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000008588 molluscum contagiosum Diseases 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 206010030861 ophthalmia neonatorum Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 208000005814 piedra Diseases 0.000 description 2
- 201000000317 pneumocystosis Diseases 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 201000002612 sleeping sickness Diseases 0.000 description 2
- 208000004441 taeniasis Diseases 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 201000005882 tinea unguium Diseases 0.000 description 2
- 208000009920 trichuriasis Diseases 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 201000000752 white piedra Diseases 0.000 description 2
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000034950 Acinetobacter Infections Diseases 0.000 description 1
- 208000029329 Acinetobacter infectious disease Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 208000003829 American Hemorrhagic Fever Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 201000002045 Ancylostomiasis Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000033211 Ankylostomiasis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241001135700 Arcanobacterium haemolyticum Species 0.000 description 1
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 1
- 208000000104 Arthus reaction Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010055181 BK virus infection Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 208000034974 Bacteroides Infections Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 241000244181 Baylisascaris Species 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 208000034200 Bolivian hemorrhagic fever Diseases 0.000 description 1
- 201000010424 Brazilian hemorrhagic fever Diseases 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 1
- 206010073031 Burkholderia infection Diseases 0.000 description 1
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 1
- 208000006448 Buruli Ulcer Diseases 0.000 description 1
- 208000023081 Buruli ulcer disease Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 208000006339 Caliciviridae Infections Diseases 0.000 description 1
- 206010051226 Campylobacter infection Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007187 Capillariasis Diseases 0.000 description 1
- 208000028737 Carrion disease Diseases 0.000 description 1
- 208000003732 Cat-scratch disease Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 208000031976 Channelopathies Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 201000009182 Chikungunya Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 1
- 206010008803 Chromoblastomycosis Diseases 0.000 description 1
- 208000015116 Chromomycosis Diseases 0.000 description 1
- 206010009344 Clonorchiasis Diseases 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 206010061802 Cyclosporidium infection Diseases 0.000 description 1
- 201000000077 Cysticercosis Diseases 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000305506 Desmodesmus Species 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- 206010013029 Diphyllobothriasis Diseases 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000030820 Ebola disease Diseases 0.000 description 1
- 206010014096 Echinococciasis Diseases 0.000 description 1
- 208000009366 Echinococcosis Diseases 0.000 description 1
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 1
- 208000000966 Enoplida Infections Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010014909 Enterovirus infection Diseases 0.000 description 1
- 206010014979 Epidemic typhus Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000007985 Erythema Infectiosum Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016675 Filariasis lymphatic Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017564 Fusobacterium infections Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010017916 Gastroenteritis staphylococcal Diseases 0.000 description 1
- 201000003950 Geotrichosis Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 201000003641 Glanders Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000000807 Gnathostomiasis Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010061190 Haemophilus infection Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241001335250 Heartland virus Species 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000025164 Hendra virus infection Diseases 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 206010020376 Hookworm infection Diseases 0.000 description 1
- 241000046923 Human bocavirus Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 208000007924 IgA Deficiency Diseases 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 208000024781 Immune Complex disease Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 241000589014 Kingella kingae Species 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 208000004023 Legionellosis Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 208000037263 Lymphatic filariasis Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010066226 Metapneumovirus infection Diseases 0.000 description 1
- 201000000090 Microsporidiosis Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000041810 Mycetoma Species 0.000 description 1
- 206010066289 Mycobacterium ulcerans infection Diseases 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 241000204051 Mycoplasma genitalium Species 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 208000006123 Myiasis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010064034 Nipah virus infection Diseases 0.000 description 1
- 206010029443 Nocardia Infections Diseases 0.000 description 1
- 206010029444 Nocardiosis Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 208000010598 Oroya fever Diseases 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 206010033767 Paracoccidioides infections Diseases 0.000 description 1
- 201000000301 Paracoccidioidomycosis Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 241000517324 Pediculidae Species 0.000 description 1
- 241000517307 Pediculus humanus Species 0.000 description 1
- 201000000376 Pediculus humanus capitis infestation Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 241001326499 Piedraia hortae Species 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010054161 Pontiac fever Diseases 0.000 description 1
- 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 description 1
- 208000031732 Post-Lyme Disease Syndrome Diseases 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 241000517305 Pthiridae Species 0.000 description 1
- 201000004360 Pthirus pubis infestation Diseases 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 208000004364 Rhinosporidiosis Diseases 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- 241000606723 Rickettsia akari Species 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 201000004282 Rickettsialpox Diseases 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000369757 Sapovirus Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039915 Selective IgA immunodeficiency Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 208000008582 Staphylococcal Food Poisoning Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 206010042254 Strongyloidiasis Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010043865 Tinea blanca Diseases 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 206010043871 Tinea nigra Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000025884 Treponema infectious disease Diseases 0.000 description 1
- 208000035055 Treponemal Infections Diseases 0.000 description 1
- 206010044608 Trichiniasis Diseases 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 1
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 1
- 201000009693 Venezuelan hemorrhagic fever Diseases 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 206010047504 Visceral Larva Migrans Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 201000006449 West Nile encephalitis Diseases 0.000 description 1
- 206010057293 West Nile viral infection Diseases 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 241000244005 Wuchereria bancrofti Species 0.000 description 1
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 206010048249 Yersinia infections Diseases 0.000 description 1
- 208000025079 Yersinia infectious disease Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 208000035994 Yersinia pseudotuberculosis Infections Diseases 0.000 description 1
- 208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 description 1
- 208000001455 Zika Virus Infection Diseases 0.000 description 1
- 201000004296 Zika fever Diseases 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- 201000007691 actinomycosis Diseases 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 201000005638 acute proliferative glomerulonephritis Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 201000010645 angiostrongyliasis Diseases 0.000 description 1
- 208000005067 anisakiasis Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 208000007456 balantidiasis Diseases 0.000 description 1
- 206010004145 bartonellosis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 201000003595 bejel Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 206010004975 black piedra Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000006824 bubonic plague Diseases 0.000 description 1
- 201000004927 campylobacteriosis Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003280 chronobiological effect Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 201000002641 cyclosporiasis Diseases 0.000 description 1
- 201000008167 cystoisosporiasis Diseases 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 201000004587 dientamoebiasis Diseases 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000008576 dracunculiasis Diseases 0.000 description 1
- 208000006036 elephantiasis Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000005901 endemic typhus Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 206010016235 fasciolopsiasis Diseases 0.000 description 1
- 208000005239 filarial elephantiasis Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 201000000128 gnathomiasis Diseases 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 201000009162 human monocytic ehrlichiosis Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 208000007188 hymenolepiasis Diseases 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 201000007156 immunoglobulin alpha deficiency Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000011422 infant botulism Diseases 0.000 description 1
- 208000019715 inherited Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000037941 meningococcal disease Diseases 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 201000001198 metagonimiasis Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 201000007524 mucormycosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000003177 ocular onchocerciasis Diseases 0.000 description 1
- 208000002042 onchocerciasis Diseases 0.000 description 1
- 208000003692 opisthorchiasis Diseases 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 206010033794 paragonimiasis Diseases 0.000 description 1
- 201000005989 paraneoplastic polyneuropathy Diseases 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000007865 relapsing fever Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 208000029138 selective IgA deficiency disease Diseases 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 201000002190 staphyloenterotoxemia Diseases 0.000 description 1
- 238000012030 stroop test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000009642 tinea barbae Diseases 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000003982 trichinellosis Diseases 0.000 description 1
- 201000007588 trichinosis Diseases 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 230000028063 type III hypersensitivity Effects 0.000 description 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 230000027285 ultradian rhythm Effects 0.000 description 1
- 208000016808 vibrio vulnificus infectious disease Diseases 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 201000009482 yaws Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/162—Testing reaction times
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/02405—Determining heart rate variability
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6887—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient mounted on external non-worn devices, e.g. non-medical devices
- A61B5/6898—Portable consumer electronic devices, e.g. music players, telephones, tablet computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7253—Details of waveform analysis characterised by using transforms
- A61B5/726—Details of waveform analysis characterised by using transforms using Wavelet transforms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/80—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
Definitions
- This invention relates to a prediction of wellness of a user with monitoring from portable monitoring devices.
- a method for monitoring a wellness of a user.
- a wellness-relevant parameter representing the user is monitored at a portable device over a defined period to produce a time series for the wellness-relevant parameter.
- a first set and a second set of either cognitive assessment data or psychosocial assessment data are obtained for the user at respective first and second times in the defined period.
- a value is assigned to the user via a predictive model according to the time series for the wellness-relevant parameter, the first set of either cognitive assessment data or psychosocial assessment data, and the second set of either cognitive assessment data or psychosocial assessment data.
- a system includes a wearable device that monitors a wellness-relevant parameter representing a user over a defined period to produce a time series for the monitored parameter.
- a portable device receives a first set and a second set of either cognitive assessment data or psychosocial assessment data for the user at respective first and second times in the defined period.
- a predictive model assigns a value to the user according to the time series for the wellness-relevant parameter, the first set of either cognitive assessment data or psychosocial assessment data, and the second set of either cognitive assessment data or psychosocial assessment data.
- a method for monitoring a wellness of a user.
- a plurality of wellness-relevant parameters representing the user are monitored at a wearable device over a defined period to produce respective time series for the monitored parameter.
- a set of features representing the user are extracted from the time series for the plurality of wellness-relevant parameters.
- the set of features includes a predicted value for at least one of the plurality of wellness-relevant parameters.
- a value is assigned to the user via a predictive model according to the set of features.
- FIG. 1 illustrates a system for monitoring the wellness of a user in accordance with an aspect of the present invention
- FIG. 2 is a schematic example of the system of FIG. 1 using a plurality of portable monitoring devices
- FIG. 3 is a screenshot of a reaction time test from an example cognitive assessment application
- FIG. 4 is a screenshot of an attention test from an example cognitive assessment application
- FIGS. 5 and 6 are screenshots of a response inhibition test from an example cognitive assessment application
- FIG. 7 is a screenshot of a working memory (1 -back) test from an example cognitive assessment application
- FIG. 8 is a screenshot of a working memory (2-back) test from an example cognitive assessment application
- FIG. 9 illustrates example questions for a first survey that is completed in the morning for an example of the system used to predict the onset of symptoms from COVID-19;
- FIG. 10 illustrates example questions for a second survey that is completed in the evening for the example of FIG. 9;
- FIG. 11 illustrates a simplified example of a map of risk scores that could be generated for a target location
- FIG. 12 illustrates graphs of several wellness-related parameters over a time period before an outbreak of an infectious disease
- FIG. 13 illustrates graphs of the parameters of FIG. 12 during an outbreak
- FIG. 14 illustrates a radar plot comparing average values for various wellness-relevant parameters for individuals infected with COVID-19 against the general population
- FIG. 15 illustrates one example of a method for monitoring the wellness of a user
- FIG. 16 illustrates another example for monitoring the wellness of a user
- FIG. 17 is a schematic block diagram illustrating an exemplary system of hardware components.
- the term “wellness” as used herein in intended to refer to the mental, physical, cognitive, social, and emotional health of a user and should be construed to cover each of the health, function, balance, resilience, homeostasis, disease, and condition of the user.
- the wellness of the user can relate to the readiness of the user to perform job-related functions, the susceptibility of the user to an infectious disease, the ability of the user to recover from an infectious disease, the exhibition of symptoms of an infectious disease by the user, the degree to which the user exhibits symptoms of an infectious disease, the ability to recover from an infectious disease, the effects of vaccines or other therapeutic substances on the user, including both efficacy and side effects, and the ability to avoid reinfection by a previously contracted infectious disease.
- a “wellness-relevant parameter” is a physiological, cognitive, sensory (e.g., smell, taste, vision, sweat, hearing, etc.), psychosocial, or behavioral parameter that is relevant to the wellness of a user.
- a “biological rhythm” is any chronobiological phenomenon that affects human beings, including but not limited to, circadian rhythms, ultradian rhythms, infradian rhythms, diurnal cycle, sleep/wake cycles, and patterns of life.
- a “portable monitoring device,” as used herein, refers to a device that is worn by, carried by, or implanted within a user that incorporates either or both of an input device and user interface for receiving input from the user and sensors for monitoring either a wellness-relevant parameter or a parameter that can be used to calculate or estimate a wellness-relevant parameter.
- Examples include wearables, such as smartwatches, rings, and similar devices, mobile devices, such as smartphones, and tablets, and laptop or notebook computers.
- index is intended to cover composite statistics and Al findings derived from a series of observations and used as an indicator or measure.
- An index can be an ordinal, continuous, or categorical value representing the observations and correlations, and should be read to encompass statistics traditionally referred to as “scores ” as well as the more technical meaning of index.
- Psychosocial assessment data includes psychosocial, behavioral, and stress related parameters that can be used to assess the functionality and stress level of a user. Each of the parameters listed in Table 3 is an example of psychosocial assessment data.
- Cognitive assessment data represents any of executive function, decision making, working memory, attention, and fatigue of a user as assessed by a one or more cognitive tests.
- Each of the parameters listed in Table 2 is an example of psychosocial assessment data.
- FIG. 1 illustrates a system 100 for monitoring the health, wellness, and functional state of a user in accordance with an aspect of the present invention.
- the system 100 includes a plurality of portable monitoring devices 102 and 110 that includes sensors for monitoring systems tracking the wellness parameters for the user.
- a given portable monitoring device e.g., 102
- wellness-relevant parameters can include at least physiological, cognitive, psychosocial, sensory, and behavioral parameters. Table I provides non-limiting examples of physiological parameters that can be measured and exemplary tests, devices, and methods, to measure the physiological parameters.
- the physiological parameters can be measured via wearable or implantable devices as well as self-reporting by the user via applications in a mobile device, which facilitates measuring these physiological parameters in a naturalistic, non-clinical setting.
- a smart watch can be used to measure the user’s heart rate, heart rate variability, body temperature, blood oxygen saturation, movement, and sleep. These values can also be subject to a diurnal analysis to estimate variability and reviewed in view of expected changes due to biological rhythms, as well as deviations from an expected pattern of biological rhythms.
- the biological rhythms of a user can be tracked for a predetermined period (e.g., ten days), to establish a normal pattern of biological rhythms.
- the cognitive parameters can be assessed by a battery of cognitive tests that measure, for example, executive function, decision making, working memory, attention, and fatigue.
- Table II provides non-limiting examples of cognitive parameters that are gamified and that can be measured and exemplary methods and tests/tasks to measure such cognitive parameters.
- These cognitive tests can be administered in a clinical/laboratory setting or in a naturalistic, non-clinical setting such as when the user is at home, work or other non-clinical setting.
- a smart device such as a smartphone, tablet, or smart watch, can facilitate measuring these cognitive parameters in a naturalistic, non-clinical setting.
- the Erikson Flanker, N-Back and Psychomotor Vigilance Tasks can be taken via an application on a smart phone, tablet, or smart watch.
- Table III provides non-limiting examples of psychosocial, behavioral, and stress related parameters that can be measured and exemplary tests, devices, and methods, to measure the behavioral parameters.
- the behavioral and psychosocial parameters can measure the user’s functionality, such as the user’s movement via wearable devices as well as subjective/self-reporting questionnaires. These parameters can also be used to quantify an overall stress level of the user that is updated at regular intervals.
- the subjective/self-reporting questionnaires can be collected in a clinical/laboratory setting or in a naturalistic, in the wild, non-clinical setting such as when the user is at home, work, or other non-clinical setting.
- a smart device such as a smartphone, tablet, or personal computer can be used to administer the subjective/self-reporting questionnaires.
- embedded accelerometers and cameras these smart devices can also be used to capture the user’s movements as well as facial expression analysis to analyze the user’s facial expressions that could indicate mood, anxiety, depression, agitation, and fatigue.
- clinical data can also be part of the multi dimensional feedback approach to predicting wellness.
- Such clinical data can includes, for example, the user’s clinical state, the user’s medical history (including family history), employment information, and residential status.
- the remote server that analyzes the data collected by the portable monitoring devices 102 and 110.
- the remote server 120 can be implemented as a dedicated physical server or as part of a cloud server arrangement. In addition to the remote server, data can be analyzed on the local device itself and/or in a federated learning mechanism.
- Information received from the portable monitoring devices 102 and 110 is provided to a feature extractor 122 that extracts a plurality of features for use at a predictive model 124.
- the feature extractor 122 determines categorical and continuous parameters representing the wellness-relevant parameters.
- the parameters can include descriptive statistics, such as measures of central tendency (e.g., median, mode, arithmetic mean, or geometric mean) and measures of deviation ⁇ e.g., range, interquartile range, variance, standard deviation, etc.) of time series of the monitored parameters, as well as the time series themselves.
- the feature extractor 124 can perform a wavelet transform on the time series of values for one or more parameters to provide a set of wavelet coefficients. It will be appreciated that the wavelet transform used herein is two-dimensional, such that the coefficients can be envisioned as a two-dimensional array across time and either frequency or scale.
- W a (n), produced in a wavelet decomposition can be defined as: [0039] wherein ⁇ is the wavelet function, Mis the length of the time series, and a and n define the coefficient computation locations.
- the wavelet coefficients can be used as individual features as well as aggregated to make composite features.
- a center of the mass represented as an ordered pair of time and either frequency or scale, can be used to provide features at the predictive model 124.
- one or more weighted combination of wavelet coefficients can be used as features, with the weights for each combination determined during a training process of the predictive model.
- the wellness-relevant parameters can be used to assign a plurality of categorical parameters to the user according to thresholds for wellness-relevant parameters or rule sets that act upon time series of values for the wellness-relevant parameters, for example, representing the presence or absence of a given condition or behavior.
- the predictive model 124 can also utilize user data 126 stored at the remote server 120, including, for example, employment information (e.g., title, department, shift), age, sex, home zip code, genomic data, nutritional information, medication intake, household information ⁇ e.g., type of home, number and age of residents), social and psychosocial, consumer spending and profiles, financial, food safety, physical abuse, and relevant medical history.
- the model can combine multiple users to interact together to refine prediction such as social model of spouse, children, family, co-workers, friends and others.
- the predictive model 124 can utilize one or more pattern recognition algorithms, each of which analyze the extracted features or a subset of the extracted features to assign a continuous or categorical parameter to the user.
- the assigned parameter can represent a predicted “burnout” of the user, that is, a predicted decrease in cognitive function, due to stress, fatigue, or illness, to an extent that will materially affect job performance.
- sleep and activity data can be used along with results from a cognitive assessment and mood reporting applications to provide a continuous index representing the degree of burnout experienced by the user.
- index can be replaced with a categorical classification ⁇ e.g., “near baseline”, “reduced”, “impaired”) in some implementations, for example, by applying one or more decision thresholds to the index.
- a categorical classification e.g., “near baseline”, “reduced”, “impaired”
- the predictive model 124 can be used to provide an index representing an internal marker of brain body balance, homeostasis, resilience, and wellness.
- the predictive model 124 can be used to provide an index representing a measure of homeostasis for the user or to predict levels of the autonomic nervous system tone, as well as certain biomarkers representing various body organs, the eye, the cardiovascular system, the gastrointestinal tract, GU, Immune and endocrine systems, including glucose, C-reactive protein, and IL-6.
- the predictive model 124 can predict a present or future pathogen (e.g., virus, bacteria, fungus, prion) concentration in a given tissue or bodily fluid of a patient.
- pathogen e.g., virus, bacteria, fungus, prion
- the predictive model 124 wherein the value represents can represent an expected degree of immunity provided to the user by immunization.
- the output of predictive model can represent an expected concentration of antibodies associated with a given vaccine in the blood of the user after a predetermined period following the immunization.
- the wellness-relevant data can be used to provide a continuous index representing the risk posed to the user by a specific illness or class of illnesses ⁇ e.g., immune disorders, cytokine storm, cancers, and infectious diseases).
- the index can represent a risk of infection, risk of being contagious, expressed, for example, as a predicted time for the individual to become contagious or a predicted virus PCR (polymerase chain reaction) levels in the nasopharynx and mouth and saliva, or a blood test, a predicted time to an onset of symptoms, a probability of recovery from a potential infection, or a single value representing a blend of two or more of these factors.
- Immune disorders include autoimmune disorders, hypersensitivity syndromes, immune deficiency disorders, and combinations thereof. Such immune disorders can be caused by cell-mediated immunity (T lymphocytes), humoral immunity (B lymphocytes) and immune tolerance. Immune disorders may result in destruction of body tissue, abnormal growth of an organ, and/or changes in organ function. An immune disorder may affect one or more organ or tissue types.
- An autoimmune disorder is a type of immune disorder resulting from an abnormal or exaggerated adaptive immune response that targets healthy cells or tissues that should not normally cause an immune reaction in the body.
- Autoimmune disorders include disorders in line with Witebsky's Postulates. These disorders can include multiple sclerosis, ankylosing spondylitis, rheumatoid arthritis, celiac disease, myositis, myasthenia gravis, Addison's disease, lupus, hemolytic anemia, vitiligo, scleroderma, psoriasis, Hashimoto's disease, Addison's disease, Grave's disease, reactive arthritis, Sjogren's syndrome, nephritis, chronic Lyme disease, vasculitis, endocarditis, alopecia areata, urticaria, vasculitis, uveitis, pemphigus, Fibromyalgia, thrombophelebitis, erythema nodusum, dermatitis, eczema, Type 1 Diabetes, temporal arteritis, Crohn's Disease, Behcet's disease,
- Hypersensitivity syndromes include immediate (Type I) hypersensitivity, antibody-mediated (Type II) hypersensitivity, immune complex- medicated (Type III) hypersensitivity, and cell-mediated (Type IV) hypersensitivity.
- Type I hypersensitivity disorders are chronic or acute allergies, atopic forms of bronchial asthma, and anaphylaxis.
- Type II hypersensitivity syndromes are autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pemphigus vulgaris, vasculitis caused by antineutrophil cytoplasmic antibodies, Goodpasture syndrome, acute rheumatic fever, myasthenia gravis, Graves’ disease, insulin-resistant diabetes, and pernicious anemia.
- Type II hypersensitivity syndromes may be caused by the production of antibodies that bind to non-self antibodies, such as after an allogenic transplantation resulting in organ rejection; blood-group incomparability resulting in hemolysis; antibodies that bind to tumor-associated antigens resulting in paraneoplastic syndromes, neuropathies, and channelopathies, for example.
- Type II hypersensitivity may also be caused by antibodies directed against cell-membrane bound medications resulting in medication-induced cell death, such as heparin-induced thrombocytopenia, for example.
- Type III hypersensitivity disorders are systemic lupus erythematosus, poststreptococcal glomerulonephritis, acute glomerulonephritis, serum sickness, Arthus reaction, reactive arthritis, and polyarteritis nodosa.
- Type IV hypersensitivity syndromes are contact dermatitis, multiple sclerosis, type 1 diabetes, transplant rejection, rheumatoid arthritis, tuberculosis, and peripheral neuropathy.
- Immune deficiency disorders include primary immunodeficiency disorders and secondary immunodeficiency disorders.
- primary immunodeficiency disorders are X-linked agammaglobulinemia, common variable immunodeficiency, isolated IgA deficiency, hyper-lgM syndrome, DiGeorge syndrome, severe combined immunodeficiency disease (SCID), Wiskott-Aldrich syndrome, and genetic deficiencies of the complement system.
- secondary immunodeficiency disorders are Acquired Immunodeficiency Syndrome (AIDS), human immunodeficiency virus (HIV) infection, combined immune deficiency syndrome (CIDS), and a spinal cord injury-induced immune depression syndrome (SCI-IDS).
- AIDS Acquired Immunodeficiency Syndrome
- HAV human immunodeficiency virus
- CIDS combined immune deficiency syndrome
- SCI-IDS spinal cord injury-induced immune depression syndrome
- Non-limited examples of infectious disease include Acinetobacter infections, Actinomycosis, African sleeping sickness (African trypanosomiasis), AIDS (acquired immunodeficiency syndrome), Amoebiasis, Anaplasmosis, Angiostrongyliasis, Anisakiasis, Anthrax, Arcanobacterium haemolyticum infection, Argentine hemorrhagic fever, Ascariasis, Aspergillosis, Astrovirus infection, Babesiosis, Bacillus cereus infection, Bacterial meningitis, Bacterial pneumonia, Bacterial vaginosis, Bacteroides infection, Balantidiasis, Bartonellosis, Baylisascaris, infection, BK virus infection, Black piedra, Blastocystosis, Blastomycosis, Venezuelan hemorrhagic fever, Botulism (and Infant botulism), Brazilian hemorrhagic fever, Brucel
- Tinea barbae barber's itch
- Tinea capitis ringworm of the scalp
- Tinea corporis ringworm of the body
- Tinea cruris Tinea manum
- Tinea nigra Tinea pedis (athlete’s foot)
- Tinea unguium onychomycosis
- Tinea versicolor Tinea versicolor
- Toxocariasis ocular larva migrans (OLM))
- Toxocariasis visceral larva migrans (VLM)
- Toxoplasmosis Trachoma, Trichinosis, Trichomoniasis, Trichuriasis (whipworm infection)
- Tuberculosis Tularemia
- Typhoid fever Typhoid fever
- Typhus fever Ureaplasma urealyticum infection
- an arbitration element can be utilized to provide a coherent result from the plurality of models.
- the training process of a given classifier will vary with its implementation, but training generally involves a statistical aggregation of training data into one or more parameters associated with the output class.
- the training process can be accomplished on a remote system and/or on the local device or wearable, app.
- the training process can be achieved in a federated or non-federated fashion.
- rule- based models such as decision trees
- domain knowledge for example, as provided by one or more human experts, can be used in place of or to supplement training data in selecting rules for classifying a user using the extracted features.
- Any of a variety of techniques can be utilized for the classification algorithm, including support vector machines, regression models, self-organized maps, fuzzy logic systems, data fusion processes, boosting and bagging methods, rule-based systems, or artificial neural networks.
- Federated learning is a machine learning technique that trains an algorithm across multiple decentralized edge devices or servers holding local data samples, without exchanging their data samples. This approach stands in contrast to traditional centralized machine learning techniques where all data samples are uploaded to one server, as well as to more classical decentralized approaches which assume that local data samples are identically distributed. Federated learning enables multiple actors to build a common, robust machine learning model without sharing data, thus addressing critical issues such as data privacy, data security, data access rights, and access to heterogeneous data.
- an SVM classifier can utilize a plurality of functions, referred to as hyperplanes, to conceptually divide boundaries in the N-dimensional feature space, where each of the N dimensions represents one associated feature of the feature vector.
- the boundaries define a range of feature values associated with each class. Accordingly, an output class and an associated confidence value can be determined for a given input feature vector according to its position in feature space relative to the boundaries.
- the SVM can be implemented via a kernel method using a linear or non-linear kernel.
- An ANN classifier comprises a plurality of nodes having a plurality of interconnections.
- the values from the feature vector are provided to a plurality of input nodes.
- the input nodes each provide these input values to layers of one or more intermediate nodes.
- a given intermediate node receives one or more output values from previous nodes.
- the received values are weighted according to a series of weights established during the training of the classifier.
- An intermediate node translates its received values into a single output according to a transfer function at the node. For example, the intermediate node can sum the received values and subject the sum to a binary step function.
- a final layer of nodes provides the confidence values for the output classes of the ANN, with each node having an associated value representing a confidence for one of the associated output classes of the classifier.
- ANN classifiers are fully-connected and feedforward.
- a convolutional neural network includes convolutional layers in which nodes from a previous layer are only connected to a subset of the nodes in the convolutional layer.
- Recurrent neural networks are a class of neural networks in which connections between nodes form a directed graph along a temporal sequence. Unlike a feedforward network, recurrent neural networks can incorporate feedback from states caused by earlier inputs, such that an output of the recurrent neural network for a given input can be a function of not only the input but one or more previous inputs.
- LSTM Long Short-Term Memory
- LSTM Long Short-Term Memory
- a rule-based classifier applies a set of logical rules to the extracted features to select an output class. Generally, the rules are applied in order, with the logical result at each step influencing the analysis at later steps.
- the specific rules and their sequence can be determined from any or all of training data, analogical reasoning from previous cases, or existing domain knowledge.
- One example of a rule-based classifier is a decision tree algorithm, in which the values of features in a feature set are compared to corresponding threshold in a hierarchical tree structure to select a class for the feature vector.
- a random forest classifier is a modification of the decision tree algorithm using a bootstrap aggregating, or “bagging” approach.
- multiple decision trees are trained on random samples of the training set, and an average (e.g., mean, median, or mode) result across the plurality of decision trees is returned.
- an average e.g., mean, median, or mode
- the result from each tree would be categorical, and thus a modal outcome can be used.
- the predictive model 124 can include a constituent model that predicts future values for wellness-relevant parameters, such as a convolutional neural network that is provided with one or more two-dimensional arrays of wavelet transform coefficients as an input.
- the wavelet coefficients detect not only changes in time, but also in temporal patterns, and can thus reflect changes in the ordinary biological rhythms of the user.
- the wellness relevant parameters predicted by the constituent models can include measured parameters such as heart rate, temperature, and heart rate variability as well as symptoms such as headaches, fatigue, shortness of breath, coughing, and sleep disruption. It will be appreciated that a given constituent model can use data in addition to the wavelet coefficients, such as other measured features and user data 126 to provide these predictions.
- the output of the predictive model 124 can be a categorical parameter representing a status of the user, such as “infected” or “not infected”, “contagious” or “not contagious”, or “recovered” or “not recovered.”
- the categorical parameter can represent whether an individual can be admitted immediately, denied admission, or subjected to further screening.
- a categorical parameter can also represent ranges of likelihoods for a current or predicted status.
- the output of the predictive model 124 can be a continuous parameter, such as a likelihood of a predicted or current status.
- the predictive model 124 can include one or more constituent models that predict a value for a wellness-relevant parameter at a future time.
- a given model can predict a heart rate or temperature for a user at a future time (e.g., in three days) based on received data from the feature extractor 122 and stored user data 126. These predicted values can be provided to a user or utilized as inputs to additional models to predict a status of the user at the future time.
- the predictive model 124 includes a plurality of convolutional neural networks, each configured to predict a future value for a wellness-relevant parameter, with the predicted values from the plurality of convolutional neural networks used to predict a future status of the user.
- the predictive model 124 can include a feedback component 128 can tune various parameters of the predictive model 124 based upon the accuracy of predictions made by the model.
- the feedback component 128 can be shared by a plurality of predictive models 124, with the outcomes for users associated with each predictive model compared to the outcomes predicted by the output of the model.
- Parameters associated with the model such as thresholds for producing categorical inputs or outputs from continuous values, can be adjusted according to the differences in the actual and predicted outcomes.
- a continuous output of the system can be compared to a threshold value to determine if the patient is infectious or non- infectious. This threshold can be varied by the feedback model 128 to increase the accuracy of the determination.
- the predictive model 124 can obtain feedback at the level of the individual model. For example, in a predictive model 124 using constituent models to predict future values of wellness-relevant parameters, the model receives consistent feedback as to the accuracy of these predictions once the wellness relevant parameter is measured. This feedback can be used to adjust parameters of the model, including individualized thresholds for that user to produce categorical inputs or outputs from continuous values, or baseline values for biological rhythms associated with the patient. Alternatively, feedback can be provided from a final output of the model and compared to other data, such as a user-reported status ⁇ e.g., symptomatic or asymptomatic for a given condition), to provide feedback to the model.
- a user-reported status ⁇ e.g., symptomatic or asymptomatic for a given condition
- a reinforcement learning approach can be used to adjust the model parameters based on the accuracy of either predicted future values of wellness-relevant parameters at intermediate stages of the predictive model 124 or the output of the predictive model.
- a decision threshold used to generate a categorical output from a continuous index produced by the predictive model 124 can be set at an initial value based on feedback from a plurality of models from previous users and adjusted via the reinforcement model to generate a decision threshold specific to the user.
- FIG. 2 is a schematic example 150 of the system of FIG. 1 using a plurality of portable monitoring devices 152, 154, and 160.
- the first and second portable monitoring devices 152 and 154 are wearable devices, worn on the wrist and finger, respectively.
- Wellness-relevant parameters monitored by the first and second portable monitoring devices 152 and 154 can include, for example, heart rate, heart rate variability, metrics of sleep quality, biological rhythm variations, metrics of sleep quantity, physical activity of the user, body orientation, movement, arterial blood pressure, respiratory rate, peripheral arterial oxyhemoglobin saturation, as measured by pulse oximetry, maximum oxygen consumption, temperature, and temperature variation.
- Wearable devices can include any wearable items implemented with appropriate sensors, including watches, wristbands, rings, headbands, headbands, and other wearable items that can maintain sensors in an appropriate position for monitoring the wellness-relevant parameters. It will be appreciated that a given wearable device 152 and 154 can monitor many of these parameters with great frequency (e.g., every five minutes) allowing for a detailed time series of data to be generated.
- the system 150 can further include a mobile device 160 that communicates with the first and second portable monitoring devices 152 and 154 via a local transceiver 162.
- the mobile device 160 can also include a graphical user interface 164 that allows a user to interact with one or more data gathering applications 166 stored at the base unit.
- One example of a possible data gathering applications can include a cognitive assessment application that tests various measures of cognitive function. These can include working memory, attention, and response inhibition, fatigue, cognition. Further, these metrics can be compared to an established baseline to estimate a measure of fatigue for the user. Screenshots from an example cognitive assessment application are provided as FIGS. 3-8.
- Another data gathering application can include a questionnaire application that allows the user to self-report symptoms, mood, mental, physical, and emotional states, and stress.
- FIG. 9 illustrates example questions for a first survey that is completed in the morning for an example of the system used to predict the onset of symptoms from COVID-19.
- FIG. 10 illustrates example questions for a second survey that is completed in the evening for this example.
- the data gathering applications 166 can be selected and configured to monitor each of:
- the mobile device 160 further comprises a network transceiver 168 via which the system 150 communicates with a remote server 170 via a local area network or Internet connection.
- the remote server 170 includes a predictive model implemented as a recurrent neural network, specifically a network with a long short-term memory architecture.
- wellness-relevant parameters from the wearable devices 152 and 154 such as temperature, in combination with questionnaire responses and cognitive assessment, can be provided to the predictive model as time series along with other relevant data.
- An output of the model is an index representing risk posed to the user by COVID-19.
- data can be collected from a plurality of users who may be socially connected, for example, as family, coworkers, or friends.
- An example is the concept of “herd immunity” computed as a social context around an individual.
- Social connections between users can be self-reported or derived from self-reported data, or, in one example, determined through analysis of location history from the mobile devices of monitored users.
- location data or proximity sensors which detect portable monitoring devices associated with other users within a threshold distance, might allow for instances of frequent spatial proximity that are not deliberate social contact (e.g., sharing a common vehicle for public transportation.)
- Bluetooth or similar short-range communication between mobile devices carried by users can be used to determine that users have been spatially proximate.
- An index indicating susceptibility or contraction to an infectious disease could be used as part of a predictor for other, connected individuals. This data could also be used to predict locations at which a disease might spread, allowing for an artificial intelligence driven smart social distancing. It will be appreciated that information gathered from users will be stored in encrypted form and shared only after removal of personally identifying data to preserve users’ privacy.
- a high traffic location such as a retail store, an airport, college campus, school, or hospital, could have a number of Bluetooth beacons at known locations. As users pass the beacons, the Bluetooth transceiver in their mobile device will interact with the beacon, with an identifier for the user and a time stored for each interaction. These values, as well as other location and proximity information collected by the application, can be employed for contact tracing as well as for determining the risk of infection associated with various locations.
- a similar process can be performed using geolocation data collected by a GPS receiver, with users passing through a geofenced region associated with a given location recorded or the presence of infected or contagious users passing through a dynamic geofence associated with each device recorded.
- Location data from user devices and/or designed Bluetooth beacons can be used to generate a mapping of infection risk across a region of interest.
- the presence of user who reports symptoms associated with a given infectious disease via one of the data gathering applications 166 can be assigned to a given location.
- both users with reported symptoms and users who are predicted to be contagious from the predictive model 124 can be used to generate the risk score.
- the contribution to the risk score for users who are predicted to be contagious can be weighted according to a probability or confidence value associated with the prediction of contagiousness.
- the map can be adjusted to show a symbol, color, or other indicator of the infection, and a risk score can be generated.
- the risk score can represent a total number of infections reported at that location for a given infectious disease, a number of infections reported at that location over a defined window of time, or a number infections reported at that location, either in total or over a defined window of time divided by an area of the location to generate a value representing a density of infections in that location.
- the risk score for each location can be shown on the map.
- FIG. 11 illustrates a simplified example of a map of risk scores 180 that could be generated for a target location.
- the risk scores for locations are illustrated as three categorical values, with a first category representing no known risk of infection, a second category representing a low level of infection risk, and a third category representing an increased level of infection risk.
- the first level of infection risk is represented as locations with no shading
- the second level of infection risk is represented as locations with light shading 182
- the third level of infection risk is represented as locations with darker shading 184.
- each categorical value can be provided by applying a defined or dynamic threshold to a continuous risk score generated for each location.
- the thresholds used to define each category can be defined according to the characteristics of the user, for example, as represented by the user data 126, or by a determination of the user’s resilience to infection as determined at the predicted model 124. For example, if a user is in a high-risk category for infection (e.g., older, immunocompromised, or comorbid condition), the threshold can be lowered to represent the user’s increased risk of infection. Similarly, if the user’s resilience is determined to be lowered at a given time, the thresholds can be temporarily lowered to represent the user’s decreased ability to resist infection. Accordingly, the map can not only be personalized to a given user, but can be adjusted to represent the risk to the user at a specific time.
- a high-risk category for infection e.g., older, immunocompromised, or comorbid condition
- the generated index can be used as a preventative measure by advising a susceptible individual to avoid social contact or predicting and forecasting contagiousness.
- a susceptible individual For example, an individual known to be susceptible to or about to become contagious with a particular infectious disease might engage in enhanced social distancing until their condition improves.
- a supervisor might remove employees that are particularly susceptible or likely to become contagious from direct contact with customers, particularly in a health care setting.
- susceptibility and forecasted contagiousness can be obtained within a population, individuals forecasted to be contagious can be warned against contact with susceptible individuals within their social network, reducing the spread of the disease among vulnerable populations.
- Indices measuring resilience or likelihood of recovery can be used for allocating scarce medical resources. For example, individuals with a high resilience can be instructed, at least initially, to treat the disease as outpatients, as it is less likely they will develop symptoms requiring hospital care. Similarly, when drugs or medical equipment, such as ventilators, are in short supply, they can be given to patients with higher need or likelihoods of recovery to maximize the effectiveness of medical resources. In other instances the indices can guide diagnostic and medical status classifications and treatment options to be more effective by taking into account ones overall body resilience and
- FIG. 12 illustrates several wellness-relevant parameters over a time period before an outbreak of an infectious disease.
- FIG. 13 illustrates the same parameters during an outbreak. It will be noted that the average body temperature and heart rate variability at the location of interest drops, while averages for heart rate as well as measures of readiness and activity fall as the outbreak progresses. It will be appreciated from FIG. 12, however, that each of these trends were evident before the outbreak was underway, and the use of the predictive model 140, specifically the evaluation of time series of these values at a recurrent network (e.g., a LSTM) can allow for prediction of the outbreak in time to take measures to reduce its severity.
- a recurrent network e.g., a LSTM
- FIG. 14 illustrates a radar plot 190 comparing average values for a set of various wellness-relevant parameters for individuals infected with COVID-19 192 against average values for the set of various wellness-relevant parameters for the general population 194.
- individuals with COVID-19 suffer moderate reductions in sleep quality and sleep duration, and show significant reductions in attention, reported wellness, and heart rate variability.
- the patient’s resting heart rate also increases significantly.
- the patient also experiences a slightly increased “workload,” that is, the cost, in the form of additional stress and fatigue, of performing daily tasks. It will be appreciated that these wellness-relevant parameters can be of particular use in identifying the onset of COVID-19 infections in asymptomatic users.
- FIGS. 15 and 16 are shown and described as executing serially, it is to be understood and appreciated that the present invention is not limited by the illustrated order, as some aspects could, in accordance with the present invention, occur in different orders and/or concurrently with other aspects from that shown and described herein. Moreover, not all illustrated features may be required to implement a method in accordance with an aspect the present invention.
- FIG. 15 illustrates one example of a method for monitoring a wellness of a user.
- a wellness-relevant parameter representing the user is monitored at a portable device over a defined period to produce a time series for the wellness relevant parameter.
- Examples of wellness-relevant parameters can include heart rate variability and body temperature, which can be monitored, for example, at a wearable device.
- a first set and a second set of either or both of cognitive assessment data and psychosocial assessment data are obtained for the user at respective first and second times in the defined period.
- the user is prompted to interact with a cognitive assessment application or psychosocial assessment application at a base unit, such as a mobile device, associated with the portable device to provide the first and second sets of assessment data.
- a value is assigned to the user via a predictive model according to the time series for the wellness-relevant parameter and the first and second sets of either cognitive assessment data or psychosocial assessment data.
- the value represents a predicted risk posed to the user by a specific illness or class of illnesses, such as a predicted or forecasted contagiousness of the user, a predicted number of days until the user will be contagious with an infectious disease, or a predicted pathogen level from DNA, RNA or protein or antibody measurements in the nose, nasopharynx, mouth, blood or other body fluid.
- the predictive model performs a wavelet decomposition on the time series for the wellness-relevant parameter to provide a set of wavelet coefficients.
- the wavelet coefficients can themselves be used as features for the predictive model or they can be aggregated into one or more composite features. For example, a weighted combination of at least a portion of the set of wavelet coefficients can be generated with the weights assigned during a training process of the predictive model. Alternatively, a center of mass of a two- dimensional array based on the set of wavelet coefficients can be generated to provide features for the predictive model.
- the predictive model can also use intermediate predictions as features in assigning the value. For example, future values for one or more wellness-related parameters can be predicted from the monitored data and then used as features in the predictive model.
- the predictive model can utilize feedback to adjust parameters associated with the predictive model, for example, via retraining of the model or the use of a reinforcement learning process on one or more specific parameters, such as decision thresholds for generating categorical values from continuous outputs.
- parameters associated with the predictive model for example, via retraining of the model or the use of a reinforcement learning process on one or more specific parameters, such as decision thresholds for generating categorical values from continuous outputs.
- an outcome associated with the user is measured and compared to the value assigned to the user via a predictive model.
- a parameter associated with the predictive model is changed according to this comparison.
- FIG. 16 illustrates another example of a method for monitoring a wellness of a user.
- a plurality of wellness-relevant parameters representing the user are monitored at a wearable device over a defined period to produce respective time series for the monitored parameter.
- a set of features representing the user are extracted from the time series for the plurality of wellness relevant parameters.
- the set of features includes a predicted value for at least one of the plurality of wellness-relevant parameters, such as heart rate variability or body temperature.
- a value is assigned to the user via a predictive model according to the set of features.
- FIG. 17 is a schematic block diagram illustrating an exemplary system 400 of hardware components capable of implementing examples of the systems and methods disclosed herein.
- the system 400 can include various systems and subsystems.
- the system 400 can be a personal computer, a laptop computer, a workstation, a computer system, an appliance, an application-specific integrated circuit (ASIC), a server, a server BladeCenter, a server farm, etc.
- ASIC application-specific integrated circuit
- the system 400 can include a system bus 402, a processing unit 404, a system memory 406, memory devices 408 and 410, a communication interface 412 (e.g., a network interface), a communication link 414, a display 416 (e.g., a video screen), and an input device 418 ⁇ e.g., a keyboard, touch screen, and/or a mouse).
- the system bus 402 can be in communication with the processing unit 404 and the system memory 406.
- the additional memory devices 408 and 410 such as a hard disk drive, server, standalone database, or other non-volatile memory, can also be in communication with the system bus 402.
- the system bus 402 interconnects the processing unit 404, the memory devices 406-410, the communication interface 412, the display 416, and the input device 418. In some examples, the system bus 402 also interconnects an additional port (not shown), such as a universal serial bus (USB) port.
- USB universal serial bus
- the processing unit 404 can be a computing device and can include an application-specific integrated circuit (ASIC).
- the processing unit 404 executes a set of instructions to implement the operations of examples disclosed herein.
- the processing unit can include a processing core.
- the additional memory devices 406, 408, and 410 can store data, programs, instructions, database queries in text or compiled form, and any other information that may be needed to operate a computer.
- the memories 406, 408, and 410 can be implemented as computer-readable media (integrated or removable), such as a memory card, disk drive, compact disk (CD), or server accessible over a network.
- the memories 406, 408 and 410 can comprise text, images, video, and/or audio, portions of which can be available in formats comprehensible to human beings.
- system 400 can access an external data source or query source through the communication interface 412, which can communicate with the system bus 402 and the communication link 414.
- the system 400 can be used to implement one or more parts of a system for monitoring a wellness of a user in accordance with the present invention.
- Computer executable logic for implementing the monitoring system resides on one or more of the system memory 406, and the memory devices 408 and 410 in accordance with certain examples.
- the processing unit 404 executes one or more computer executable instructions originating from the system memory 406 and the memory devices 408 and 410.
- the term "computer readable medium" as used herein refers to a medium that participates in providing instructions to the processing unit 404 for execution. This medium may be distributed across multiple discrete assemblies all operatively connected to a common processor or set of related processors. Specific details are given in the above description to provide a thorough understanding of the embodiments.
- the processing units can be implemented within one or more application specific integrated circuits (ASICs), digital signal processors (DSPs), digital signal processing devices (DSPDs), programmable logic devices (PLDs), field programmable gate arrays (FPGAs), processors, controllers, micro controllers, microprocessors, other electronic units designed to perform the functions described above, and/or a combination thereof.
- ASICs application specific integrated circuits
- DSPs digital signal processors
- DSPDs digital signal processing devices
- PLDs programmable logic devices
- FPGAs field programmable gate arrays
- processors controllers, micro controllers, microprocessors, other electronic units designed to perform the functions described above, and/or a combination thereof.
- the embodiments can be described as a process which is depicted as a flowchart, a flow diagram, a data flow diagram, a structure diagram, or a block diagram. Although a flowchart can describe the operations as a sequential process, many of the operations can be performed in parallel or concurrently. In addition, the order of the operations can be re-arranged. A process is terminated when its operations are completed, but could have additional steps not included in the figure. A process can correspond to a method, a function, a procedure, a subroutine, a subprogram, etc. When a process corresponds to a function, its termination corresponds to a return of the function to the calling function or the main function.
- embodiments can be implemented by hardware, software, scripting languages, firmware, middleware, microcode, hardware description languages, and/or any combination thereof.
- the program code or code segments to perform the necessary tasks can be stored in a machine readable medium such as a storage medium.
- a code segment or machine- executable instruction can represent a procedure, a function, a subprogram, a program, a routine, a subroutine, a module, a software package, a script, a class, or any combination of instructions, data structures, and/or program statements.
- a code segment can be coupled to another code segment or a hardware circuit by passing and/or receiving information, data, arguments, parameters, and/or memory contents.
- Information, arguments, parameters, data, etc. can be passed, forwarded, or transmitted via any suitable means including memory sharing, message passing, ticket passing, network transmission, etc.
- the methodologies can be implemented with modules (e.g., procedures, functions, and so on) that perform the functions described herein.
- Any machine-readable medium tangibly embodying instructions can be used in implementing the methodologies described herein.
- software codes can be stored in a memory.
- Memory can be implemented within the processor or external to the processor.
- the term “memory” refers to any type of long term, short term, volatile, nonvolatile, or other storage medium and is not to be limited to any particular type of memory or number of memories, or type of media upon which memory is stored.
- the term “storage medium” can represent one or more memories for storing data, including read only memory (ROM), random access memory (RAM), magnetic RAM, core memory, magnetic disk storage mediums, optical storage mediums, flash memory devices and/or other machine readable mediums for storing information.
- ROM read only memory
- RAM random access memory
- magnetic RAM magnetic RAM
- core memory magnetic disk storage mediums
- optical storage mediums flash memory devices and/or other machine readable mediums for storing information.
- machine-readable medium includes, but is not limited to portable or fixed storage devices, optical storage devices, wireless channels, and/or various other storage mediums capable of storing that contain or carry instruction(s) and/or data.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Artificial Intelligence (AREA)
- Signal Processing (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Developmental Disabilities (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Educational Technology (AREA)
- Social Psychology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Mathematical Physics (AREA)
- Fuzzy Systems (AREA)
- Evolutionary Computation (AREA)
- Neurosurgery (AREA)
- Multimedia (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021244627A AU2021244627A1 (en) | 2020-03-27 | 2021-03-29 | Predicting wellness of a user with monitoring from portable monitoring devices |
JP2023502877A JP2023521255A (en) | 2020-03-27 | 2021-03-29 | User Health Prediction Using Monitoring from Portable Monitoring Devices |
CA3173456A CA3173456A1 (en) | 2020-03-27 | 2021-03-29 | Predicting wellness of a user with monitoring from portable monitoring devices |
KR1020227037501A KR20230002513A (en) | 2020-03-27 | 2021-03-29 | User's health prediction by monitoring of portable monitoring device |
EP21775464.7A EP4125562A4 (en) | 2020-03-27 | 2021-03-29 | Predicting wellness of a user with monitoring from portable monitoring devices |
CN202180024902.7A CN115443093A (en) | 2020-03-27 | 2021-03-29 | Predicting a health condition of a user with monitoring from a portable monitoring device |
US17/913,190 US20230140151A1 (en) | 2020-03-27 | 2021-03-29 | Predicting wellness of a user with monitoring from portable monitoring devices |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063000607P | 2020-03-27 | 2020-03-27 | |
US63/000,607 | 2020-03-27 | ||
US202063032036P | 2020-05-29 | 2020-05-29 | |
US63/032,036 | 2020-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021195616A1 true WO2021195616A1 (en) | 2021-09-30 |
Family
ID=77890593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/024617 WO2021195616A1 (en) | 2020-03-27 | 2021-03-29 | Predicting wellness of a user with monitoring from portable monitoring devices |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230140151A1 (en) |
EP (1) | EP4125562A4 (en) |
JP (1) | JP2023521255A (en) |
KR (1) | KR20230002513A (en) |
CN (1) | CN115443093A (en) |
AU (1) | AU2021244627A1 (en) |
CA (1) | CA3173456A1 (en) |
WO (1) | WO2021195616A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114403047A (en) * | 2022-02-09 | 2022-04-29 | 上海依蕴宠物用品有限公司 | Aged animal health intervention method and system based on image analysis technology |
WO2023015353A1 (en) * | 2021-08-11 | 2023-02-16 | Immunosis Pty Ltd | Methods for determining secondary immunodeficiency |
WO2023096265A1 (en) * | 2021-11-26 | 2023-06-01 | 서울대학교병원 | Device and method for deriving severity prediction score of covid-19 patient using biological signal |
WO2024026046A1 (en) * | 2022-07-27 | 2024-02-01 | West Virginia University Board of Governors on behalf of West Virginia University | Analysis framework for evaluating human wellness |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116671906A (en) * | 2023-08-01 | 2023-09-01 | 亿慧云智能科技(深圳)股份有限公司 | Noninvasive blood glucose measurement method and noninvasive blood glucose measurement system for smart watch |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120264712A1 (en) * | 2003-04-01 | 2012-10-18 | University Of Southern California | Caries risk test for predicting and assessing the risk of disease |
US20170308671A1 (en) * | 2016-04-20 | 2017-10-26 | Bionous, LLC | Personal health awareness system and methods |
US20190307328A1 (en) * | 2006-06-30 | 2019-10-10 | Empire Ip Llc | Personal Emergency Response (PER) System |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9526455B2 (en) * | 2011-07-05 | 2016-12-27 | Saudi Arabian Oil Company | Systems, computer medium and computer-implemented methods for monitoring and improving health and productivity of employees |
US10606353B2 (en) * | 2012-09-14 | 2020-03-31 | Interaxon Inc. | Systems and methods for collecting, analyzing, and sharing bio-signal and non-bio-signal data |
KR20160055103A (en) * | 2013-03-15 | 2016-05-17 | 아담 제이 사이먼 | System and signatures for the multi-modal physiological stimulation and assessment of brain health |
WO2017212333A1 (en) * | 2016-06-07 | 2017-12-14 | NeuroSteer Ltd. | Systems and methods for analyzing brain activity and applications thereof |
US20190239791A1 (en) * | 2018-02-05 | 2019-08-08 | Panasonic Intellectual Property Management Co., Ltd. | System and method to evaluate and predict mental condition |
-
2021
- 2021-03-29 WO PCT/US2021/024617 patent/WO2021195616A1/en unknown
- 2021-03-29 US US17/913,190 patent/US20230140151A1/en active Pending
- 2021-03-29 EP EP21775464.7A patent/EP4125562A4/en active Pending
- 2021-03-29 AU AU2021244627A patent/AU2021244627A1/en active Pending
- 2021-03-29 KR KR1020227037501A patent/KR20230002513A/en unknown
- 2021-03-29 CN CN202180024902.7A patent/CN115443093A/en active Pending
- 2021-03-29 JP JP2023502877A patent/JP2023521255A/en active Pending
- 2021-03-29 CA CA3173456A patent/CA3173456A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120264712A1 (en) * | 2003-04-01 | 2012-10-18 | University Of Southern California | Caries risk test for predicting and assessing the risk of disease |
US20190307328A1 (en) * | 2006-06-30 | 2019-10-10 | Empire Ip Llc | Personal Emergency Response (PER) System |
US20170308671A1 (en) * | 2016-04-20 | 2017-10-26 | Bionous, LLC | Personal health awareness system and methods |
Non-Patent Citations (1)
Title |
---|
See also references of EP4125562A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023015353A1 (en) * | 2021-08-11 | 2023-02-16 | Immunosis Pty Ltd | Methods for determining secondary immunodeficiency |
WO2023096265A1 (en) * | 2021-11-26 | 2023-06-01 | 서울대학교병원 | Device and method for deriving severity prediction score of covid-19 patient using biological signal |
CN114403047A (en) * | 2022-02-09 | 2022-04-29 | 上海依蕴宠物用品有限公司 | Aged animal health intervention method and system based on image analysis technology |
CN114403047B (en) * | 2022-02-09 | 2023-01-06 | 上海依蕴宠物用品有限公司 | Aged animal health intervention method and system based on image analysis technology |
WO2024026046A1 (en) * | 2022-07-27 | 2024-02-01 | West Virginia University Board of Governors on behalf of West Virginia University | Analysis framework for evaluating human wellness |
Also Published As
Publication number | Publication date |
---|---|
JP2023521255A (en) | 2023-05-23 |
CN115443093A (en) | 2022-12-06 |
CA3173456A1 (en) | 2021-09-30 |
EP4125562A1 (en) | 2023-02-08 |
US20230140151A1 (en) | 2023-05-04 |
EP4125562A4 (en) | 2024-04-17 |
AU2021244627A1 (en) | 2022-11-03 |
KR20230002513A (en) | 2023-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230140151A1 (en) | Predicting wellness of a user with monitoring from portable monitoring devices | |
Karatas et al. | Big Data for Healthcare Industry 4.0: Applications, challenges and future perspectives | |
Bourechak et al. | At the confluence of artificial intelligence and edge computing in iot-based applications: A review and new perspectives | |
US11195625B2 (en) | Method for modeling behavior and depression state | |
San-Segundo et al. | Parkinson’s disease tremor detection in the wild using wearable accelerometers | |
Asri et al. | Big data in healthcare: Challenges and opportunities | |
McDonald et al. | Continuous monitoring and detection of post-traumatic stress disorder (PTSD) triggers among veterans: a supervised machine learning approach | |
Alatoun et al. | A novel low-latency and energy-efficient task scheduling framework for internet of medical things in an edge fog cloud system | |
Petrescu et al. | Machine learning methods for fear classification based on physiological features | |
Jemal et al. | A study of EEG feature complexity in epileptic seizure prediction | |
Chitra et al. | Prediction of heart disease and chronic kidney disease based on internet of things using RNN algorithm | |
Veerabaku et al. | Intelligent Bi-LSTM with architecture optimization for heart disease prediction in WBAN through optimal channel selection and feature selection | |
Muthu Ganesh et al. | Heuristic-based channel selection with enhanced deep learning for heart disease prediction under WBAN | |
Cox et al. | The promises and possibilities of artificial intelligence in the delivery of behavior analytic services | |
Rahmani et al. | Flexible-clustering based on application priority to improve iomt efficiency and dependability | |
Wang et al. | EEG and ECG-based multi-sensor fusion computing for real-time fatigue driving recognition based on feedback mechanism | |
Ebada et al. | Applying cloud based machine learning on biosensors streaming data for health status prediction | |
Arji et al. | A systematic literature review and analysis of deep learning algorithms in mental disorders | |
Aksu et al. | Mental Workload Assessment Using Machine Learning Techniques Based on EEG and Eye Tracking Data | |
Gutierrez Maestro et al. | Wearable-Based Intelligent Emotion Monitoring in Older Adults during Daily Life Activities | |
Xiao et al. | Big Data in Medical AI: How Larger Data Sets Lead to Robust, Automated Learning for Medicine | |
Bampakis et al. | UBIWEAR: An end-to-end, data-driven framework for intelligent physical activity prediction to empower mHealth interventions | |
Cooper et al. | Predicting future sedentary behaviour using wearable and mobile devices | |
Barrachina-Fernández et al. | Advanced Analysis of Electrodermal Activity Measures to Detect the Onset of ON State in Parkinson’s Disease | |
Martinez et al. | Big data and machine learning: a way to improve outcomes in population health management |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21775464 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3173456 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2023502877 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021244627 Country of ref document: AU Date of ref document: 20210329 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021775464 Country of ref document: EP Effective date: 20221027 |